Get started
Telix Pharmaceuticals: A Game-Changer in Brain Cancer ImagingTelix Pharmaceuticals Limited (ASX: TLX) has announced a significant development in its journey towards transforming brain cancer diagnostics. The company has opened an Expanded Access Program (EAP) in the United States for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET), an investigational PET agent for imaging progressive or recurrent glioma. This move comes after receiving the green light from the U.S. Food and Drug Administration (FDA), marking a major milestone for Telix in addressing the unmet medical needs in glioma imaging. The Need for Advanced Glioma Imaging Glioma is the most common and aggressive form of primary brain cancer, notoriously difficult to diagnose and monitor accurately with conventional MRI. Traditional MRI has limitations, including lack of biological specificity, dependency on blood-brain barrier disruption, and difficulty in differentiating between tumor progression and treatment-related changes. These challenges underscore the critical need for more precise imaging techniques. Dr. Patrick Wen, a renowned neurologist from Harvard Medical School and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, emphasized the potential of TLX101-CDx to revolutionize glioma imaging. "Amino acid PET imaging of the brain is increasingly used to supplement conventional imaging by MRI. TLX101-CDx (FET-PET) shows potential to provide a more rapid and conclusive diagnosis, inform treatment decisions, and deliver a new standard for the management of gliomas in the U.S.," he said. Expanded Access Program and Future Prospects The FDA's EAP, also known as 'compassionate use,' allows patients with serious or life-threatening conditions to access investigational products outside of clinical trials. This initiative by Telix ensures that glioma patients in the U.S. can benefit from TLX101-CDx even before its formal approval. David N. Cade, MD, Telix's Chief Medical Officer, highlighted the importance of this program, stating, "The opening of this expanded access program will enable us to provide continued access to this investigational agent, where there is significant unmet medical need in the U.S." Telix plans to file its New Drug Application (NDA) for TLX101-CDx with the FDA during Q3 2024, aiming to make this advanced imaging agent commercially available in the U.S. for both adult and pediatric patients. Financial Growth and Market Position Telix Pharmaceuticals has also revised its full-year revenue forecast upwards, following a robust second quarter. The company now expects revenue to fall within the range of $US490 million to $US510 million, approximately 10% higher than previous guidance. This surge in revenue is primarily driven by higher sales of its prostate cancer imaging product, Illuccix, in the U.S. Telix's shares have seen a remarkable rise, hitting a fresh record high of $20.76 before stabilizing around $19.81 on Monday Market trading. The company's CEO, Christian Behrenbruch, attributed this growth to "excellent quarterly growth in both revenue and dose volume sales of Illuccix." Despite the impressive financial performance, Telix continues to invest heavily in research and development, with plans to increase R&D spending by 40% to 50% compared to the prior year. This investment is crucial for the continued development of its innovative diagnostic solutions, including TLX101-CDx and other therapies like Zircaix for diagnosing kidney cancers. The Road Ahead Telix Pharmaceuticals is poised to make significant strides in the field of cancer diagnostics. The launch of the EAP for TLX101-CDx in the U.S. and the forthcoming NDA submission highlight the company's commitment to addressing critical gaps in glioma imaging. With its innovative products and strong financial performance, Telix is well-positioned to deliver robust growth and create substantial value for its shareholders. As the demand for advanced diagnostic solutions continues to rise, Telix's pioneering efforts in developing targeted imaging agents could set new standards in cancer care, offering hope and improved outcomes for patients worldwide. Conclusion Telix Pharmaceuticals' recent advancements and strategic initiatives underscore its potential to become a leader in the cancer diagnostics market. By addressing the critical needs in glioma imaging and leveraging its robust product pipeline, Telix ( ASX:TLX ) is on a path to achieve significant growth and impact the lives of countless patients battling cancer.
ASX:TLXLong
by DEXWireNews
LTR (ASX) chart resembles AmazonI've been looking at US stocks lately and going through the Ideas on Aussie stocks. I saw LTR and immediately thought of Amazon. There seems to be a common wave structure. The wave count technically is not Elliott Waves because: - Wave 4 on both charts enter the territory of Wave 2 - Wave 4 goes below Wave 3 on LTR. However, if you look at the general form of both charts, they are quite similar. If LTR behaves in a similar manner, then there could be quite an uptrend ahead.
ASX:LTRLong
by AuroraCharts
WR1.ASX Winsome Resources Trend Cloud Study.Winsome Resources has been Bashed Down with all the Lithium miners of the Last Year or more. Just as High Inflation is the cure for High Inflation, I surmise the same could be true for these Miners - as they are forced to shut down certain operations, thereby decreasing supply. They also become Targets for Takeovers and MA's. As my Chart depicts, I also was caught by many Bull Traps, and I am in a Loss Scenario. However, I am now seeing a potential reversal on the Trend Cloud and IMACD. Adding to my position remains very Risky and is not a recommended policy However if one got in near the recent lows & you are profitable - your Risk will be lower. As my Chart depicts, I Diarise as much information as possible using the Call-Out Tool and Price Range % to assist with my decisions. As always, please get a few outside Expert's Advice before taking Trade or Investment decisions. Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away. Regards Graham.
ASX:WR1Long
by hitchcoxg
3
Finer Market Points: ASX Top 10 Momentum Stocks: 25 Jul 2024NYSE:WTM ASX:QHL AMEX:TTT GETTEX:SKS ASX:ACW FWB:AL3 NYSE:SPR GETTEX:CYL ASX:EZZ ASX:RIM Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Waratah Minerals Limited (WTM) Quickstep Holdings Limited (QHL) Titomic Limited (TTT) SKS Technologies Group Limited (SKS) Actinogen Medical Limited (ACW) AML3D Limited (AL3) Spartan Resources Limited (SPR) Catalyst Metals Limited (CYL) EZZ Life Science Holdings Limited (EZZ) Rimfire Pacific Mining Limited (RIM)
ASX:SPR
by ch886
Simple technicals, Northern Star Resources - NST (ASX)Northern Star Resources - NST (ASX) In a long term bullish move, and medium term pullback with a recovery bounce off the 200-day moving average. We are starting to see a possible convergence on the medium-term MACD, which could lead to a recovery in the medium term, if buying continues. Full report details for members at marketmonkey.com.au Please feel free to request more Blue Chip technicals via hello@marketmonkey.com.au 🙈
ASX:NSTLong
by Market_Monkey_AU
Aristocrat Leisure - is price over extended?#ASX #ALL - Aristocrat Leisure Examining #ALL for July, the strength of buying remains moderate to strong, which is continuing to push the price higher towards the end of July. Currently on directional indicators in the Blue Chip stock analysis report (marketmonkey.com.au), the price is over extended for a second month. This over-exuberant buying tends to decline into the third month, when prices often weaken. No convergence as yet with the short-term moving averages, so price is likely to remain bullish in the very short term. Please feel free to request ASX stock analysis via hello@marketmonkey.com.au 🙈
ASX:ALL
by Market_Monkey_AU
AudinateBig watch on ASX:AD8 on a pretty strong support level. Could make a case for a triple bottom already, but I'm looking for a stronger touch. Kumo twist. Sideways consolidation on the daily. Coming up to testing the top of the cloud as support on the weekly. Don't mind the idea of buying here or DCA'ing for a period of time. Really interested to see what the price action will be like heading into 'Earnings & Revenue'. Of particular interest will be any progress made in the video space that has been much hyped. I haven't kept up enough with the news or the outlook to know when there is an expectation of revenue growth from this area.
ASX:AD8
by Swick15
Finer Market Points: ASX Top 10 Momentum Stocks: 18 Jul 2024ASX:I88 AMEX:TTT XETR:DGR NYSE:WTM GETTEX:SKS ASX:QHL GETTEX:CYL ASX:ACW ASX:EZZ FWB:AL3 Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Infinity Resources (I88) Titomic Limited (TTT) DGR Global Limited (DGR) Waratah Minerals Limited (WTM) SKS Technologies Group Limited (SKS) Quickstep Holdings Limited (QHL) Catalyst Metals Limited (CYL) Actinogen Medical Limited (ACW) EZZ Life Science Holdings Limited (EZZ) AML3D Limited (AL3)
ASX:TTT
by ch886
Liontown Resource OutlookTechnical Analysis Short-term: Watch the $1.00 support level. If it holds, there might be a short-term bounce, especially considering the increased volume at this level. Medium-term: Monitor the $1.25 support and $1.75 resistance levels. Both levels show significant volume activity, indicating strong buying and selling interest. Long-term: Significant resistance is around $2.75. A break above this level, confirmed by high volume, could indicate a potential for higher highs. Macro Analysis The latest quarterly report for Liontown Resources, dated March 2024, indicates several updates and progress compared to the previous financial report. Here are the main changes: 1. Project Completion Progress: The Kathleen Valley Lithium Project is now more than 85% complete on an earned value basis, with the process plant approximately 90% complete. This is a significant advancement compared to earlier stages. 2. Workforce and Construction Hours: The site-based workforce now exceeds 900 people, and approximately three million work hours have been recorded since construction commenced at Kathleen Valley (61204675-1) . 3. Mining Progress: Underground mining has achieved significant progress, with approximately 1,535 total development meters recorded for the March quarter Open pit mining has also advanced well, with 1.1 million bulk cubic meters mined and ore being stockpiled ahead of plant startup 4. Process Plant and Infrastructure: Commissioning of the dry plant commenced in late March 2024, with the crushing circuit energized ahead of schedule Wet plant milestones were achieved, with key areas like flotation piping and electrical well-progressed 5. Financial Position and Funding: Execution of a A$550 million debt package to support the Kathleen Valley project, ensuring sufficient funding through to first production and beyond The company's cash balance was A$358.1 million as of 31 March 2024 6. Business Readiness and Recruitment: Business readiness preparations continued to build momentum ahead of first production, with 258 full-time employees directly employed by Liontown at the end of the quarter 7. Environmental, Social, and Governance (ESG) Activities: Key ESG activities progressed, including the approval of the Kathleen Valley Mining Proposal update and the completion of heritage surveys for infrastructure construction 8. New Contracts and Agreements: The Kathleen Valley Village Services contract was awarded to Sirrom Corporation for three years Significant progress was made on the construction of the 95MW Hybrid Power Station, including the installation of solar panels and live testing of LNG gensets 9. Tailings Storage Facility and Water Management: The Tailings Storage Facility (TSF) cell 1 continues to be filled with raw water to support start-up processing operations These changes reflect significant advancements in project development, financial structuring, and operational readiness compared to previous reports, positioning Liontown Resources closer to commencing production and generating revenue from the Kathleen Valley Lithium Project.
ASX:LTRLong
by monkreet
ADRIATIC METALS - ADT - ASXCHART SETTINGS =============== Chart is Logarithmic Weekly Timeline Green boxes are FIB to the upside drawn from major pivots (marked with yellow dots) . In the box, 0.382 = top of box and 0.618 bottom of box Red Horizontal box = Major Support/Resistance zone Black Inclined Dotted line = Major Support Trend line ABOUT THE COMPANY =================== Adriatic Metals Plc is a precious and base metals explorer and developer that owns the world-class Vares silver project in Bosnia & Herzegovina and the Raska zinc deposit in Serbia. Market Cap = 1.07Billion (20/07/2024) WHAT I SEE IN CHART =================== ADT in its Logarithmic setting seems to respect the Black dotted trendline. It acted as support in the past. In the last 2 touches to the Trendline, the price also visited the FIB 50 levels of that move. This time, while its touching the Trendline, the Price just visited the 0.382 FIB level. The Horizontal Trendzone (red box) acted as support and resistance in the past. On the FIB extension there is a 1.618 to the downside. Price at that level is 3.02 (Psychological number too) THOUGHTS ========== Will it respect the Horizontal Trend Zone and Inclined Trendline this time as well ? It may pierce through both these down to FibExt 1.618 and even further down to the FIB 50 and and grab the liquidity from there, before it goes up. Need to wait and watch. It may go side-ways for sometime as well.
ASX:ADT
by stmstratum
Finer Market Points: ASX Top 10 Momentum Stocks: 17 Jul 2024ASX:I88 XETR:DGR ASX:TTT CSEMA:FBR ASX:ACW NYSE:WTM ASX:EZZ CBOE:RXM ASX:CYL GETTEX:SKS Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is published weekly on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Infinity Resources (I88) DGR Global Limited (DGR) Titomic Limited (TTT) FBR Limited (FBR) Actinogen Medical Limited (ACW) Waratah Minerals Limited (WTM) EZZ Life Science Holdings Limited (EZZ) Rex Minerals Limited (RXM) Catalyst Metals Limited (CYL) SKS Technologies Group Limited (SKS)
ASX:TTT
by ch886